Teva Announces FDA Approval And Commercial Launch Of Fentanyl Transdermal System Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil's chronic pain treatment Duragesic®. Shipment of this product has commenced.
Source: www.medicalnewstoday.comTorreyPines Therapeutics Begins Dosing In A Phase I Multiple Dose Clinical Trial Of NGX426, Oral Prodrug Of Tezampanel TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is designed to evaluate the safety, tolerability and pharmacokinetics of NGX426 when given once daily for five consecutive days.
Source: www.medicalnewstoday.comThermogard XP(TM) Studies To Be Presented At American Society Of Anesthesiologists Annual Meeting Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies, announced that four scientific posters featuring both patient cases and laboratory research in which the Thermogard XP(TM) was utilized will be presented this week at the American Society of Anesthesiologists (ASA) Annual Meeting, taking place in Orlando. Dr.
Source: www.medicalnewstoday.comPfizer Reaches Agreements In Principle To Resolve Litigation Involving Its NSAID Pain Medications - $894 Million Settlements Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID) pain medication Bextra, which Pfizer voluntarily withdrew from the U.S. market in 2005.
Source: www.medicalnewstoday.comFDA Defers Final Action On Milnacipran New Drug Application Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) (the "Companies") announced that the U.S.
Source: www.medicalnewstoday.com
# posted by Network @ 10:00 AM
